eHealth
eHealth's revenue rose 4.1% to $554 million in fiscal 2025. Its operating margin was 12.0%, up from 4.4% a year earlier. Free cash flow was −$28 million. The diluted share count rose 3.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What eHealth does
eHealth is a licensed health insurance agency that helps people in the United States compare and sign up for health plans, mostly Medicare plans for people 65 and older. Shoppers can use its websites on their own, call one of its licensed agents, which it calls benefit advisors, or mix the two through online chat. It offers thousands of plans from over 180 insurers, including Medicare Advantage, Medicare Supplement and prescription drug plans, as well as individual, family, small business, dental and vision coverage.
The service is free to consumers. eHealth is paid by the insurers, mostly through commissions on the policies it sells, often every month for as long as a member keeps the plan. It also earns fees for advertising, enrollment work and licensing its technology to insurers. It does not take on insurance risk itself. The Medicare segment made up approximately 96% of revenue in 2025; the rest came from the Employer and Individual segment. Its competitors include government-run insurance exchanges, insurers selling directly, other online brokers and local insurance agents.
Much of its sales come in the fall, during Medicare's yearly enrollment period. At the end of 2025 eHealth had 1,665 regular full-time employees, most of them in customer care and enrollment, including 163 at its subsidiary in China.
Its biggest risks, as it describes them
- Insurers can end or change their agency deals on short notice, and a few of them bring in much of its revenue.
- Complex and changing Medicare marketing rules, and legal proceedings or government inquiries over its sales practices.
- Members who drop their plans early, cutting the commissions it expects to receive over time.
- Its heavy reliance on the fall Medicare enrollment season, and on hiring and keeping licensed agents in time for it.
- Competition from government-run exchanges, insurers and other agents and brokers.
Income statement
From fiscal 2016 to 2020, earnings per share grew 202.7% a year and net income 250.7% a year, as new shares raised the share count by 48% and diluted each share's earnings. eHealth then lost money in fiscal 2021, 2022 and 2023.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 123 | 144 | 122 | 82 | 77 |
| Debt incl. finance leases | 0 | 66 | 68 | 68 | 113 |
| Net debt (negative means net cash) | −123 | −78 | −54 | −14 | 36 |
| Net debt to EBITDA | — | — | — | −0.5x | 0.5x |
| Debt to equity | 0.0x | 0.1x | 0.1x | 0.1x | 0.2x |
| Interest coverage | −148.7x | −13.5x | −2.6x | 2.1x | 6.2x |
| Current ratio | 5.4x | 6.6x | 4.9x | 3.7x | 3.4x |
| Quick ratio | 5.4x | 6.6x | 4.9x | 3.7x | 3.4x |
Cash flow
Projections
Project eHealth's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What eHealth says to expect
- Full year 2026: total revenue
Total revenue is expected to be in the range of $405.0 million to $445.0 million.
- Full year 2026: GAAP net income
GAAP net income is expected to be in the range of $8.0 million to $25.0 million.
- Full year 2026: adjusted EBITDA
Adjusted EBITDA (1) is expected to be in the range of $55.0 million to $75.0 million.
- Full year 2026: operating cash flow
Operating cash flow is expected to be in the range of $(10.0) million to $12.0 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $297,647 of eHealth shares on the open market, and 1 insider sold $81,679, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Francis S Soistman JrDirector | Sold plan | 37,297 | $1.05 | $39,162 | Form 4 |
| Aug 31, 2026 | Francis S Soistman JrDirector | Sold plan | 37,296 | $1.14 | $42,517 | Form 4 |
| Mar 6, 2026 | John Joseph DolanChief Financial Officer | Bought | 25,000 | $1.53 | $38,250 | Form 4 |
| Feb 27, 2026 | Derrick A DukeChief Executive Officer, Director | Bought | 187,969 | $1.38 | $259,397 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 5 of 9 | 4 of 9 |
| Rule of 40 | 9.8% | 13.7% | −0.9% |
| Altman Z'' | 4.68 | 4.34 | 3.81 |
| Accruals ratio | −1.9% | 2.5% | 5.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 3 of 9 | 5 of 9 | 4 of 9 |
Compare
Put eHealth side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| eHealth | FY25 | 4.1% | 12.0% | −5.0% | 7.5% | 0.5x | 4 | |
| AIFU | FY25 | −58.2% | −7.0% | −3.5% | — | — | — | Compare |
| Ethos Technologies | FY25 | 52.0% | 18.8% | 9.0% | — | — | — | Compare |
| Goosehead Insurance | FY25 | 16.1% | 20.4% | 23.6% | 75.5% | 3.0x | 5 | Compare |
| XChange TEC.INC | FY25 | 26.7% | −197.2% | — | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 193 | 191 | 251 | 506 | 583 | 538 | 405 | 453 | 532 | 554 |
| Revenue growth | 2.0% | −1.4% | 31.8% | 101.4% | 15.1% | −7.7% | −24.7% | 11.7% | 17.6% | 4.1% |
| Gross profit | 192 | 190 | 250 | 504 | 579 | 536 | 404 | 159 | 208 | 241 |
| Research and development | 9 | 8 | 7 | 8 | 9 | 10 | 12 | 14 | 12 | 14 |
| Operating income | 3 | −10 | 3 | 81 | 53 | −126 | −103 | −29 | 24 | 66 |
| Net income | 0 | 25 | 0 | 67 | 45 | −104 | −89 | −28 | 10 | 40 |
| Diluted EPS (US$) | 0.02 | 1.33 | 0.01 | 2.73 | 1.68 | −4.59 | −4.36 | −2.37 | −1.19 | −0.34 |
| Diluted shares (millions) | 18 | 19 | 20 | 24 | 27 | 27 | 27 | 28 | 29 | 30 |
| Cash flow | ||||||||||
| Cash from operations | 4 | −16 | −3 | −72 | −108 | −163 | −27 | −7 | −18 | −25 |
| Capital expenditure | 2 | 2 | 4 | 7 | 8 | 4 | 0 | 2 | 2 | 2 |
| Free cash flow | 2 | −17 | −8 | −78 | −116 | −166 | −27 | −9 | −20 | −28 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 7 | 10 | 12 | 23 | 25 | 33 | 20 | 23 | 20 | 15 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 62 | 40 | 13 | 24 | 93 | 123 | 144 | 122 | 82 | 77 |
| Debt incl. finance leases | — | 0 | 5 | 0 | 0 | 0 | 66 | 68 | 68 | 113 |
| Total assets | 109 | 359 | 439 | 742 | 1,040 | 1,149 | 1,113 | 1,113 | 1,155 | 1,262 |
| Total liabilities | −143 | 72 | 136 | 214 | 202 | 167 | 198 | 209 | 230 | 289 |
| Shareholders' equity | 252 | 287 | 303 | 527 | 838 | 750 | 651 | 606 | 588 | 592 |
| Margins and ratios | ||||||||||
| Gross margin | 99.5% | 99.7% | 99.5% | 99.5% | 99.3% | 99.6% | 99.6% | 35.1% | 39.1% | 43.5% |
| Operating margin | 1.5% | −5.0% | 1.0% | 16.1% | 9.2% | −23.4% | −25.3% | −6.4% | 4.4% | 12.0% |
| Net margin | 0.2% | 13.3% | 0.1% | 13.2% | 7.8% | −19.4% | −21.9% | −6.2% | 1.9% | 7.2% |
| Free cash flow margin | 1.1% | −9.1% | −3.1% | −15.4% | −19.8% | −30.9% | −6.7% | −1.9% | −3.8% | −5.0% |
| Rule of 40 (growth + FCF margin) | 3.1% | −10.5% | 28.7% | 85.9% | −4.7% | −38.6% | −31.4% | 9.8% | 13.7% | −0.9% |
| Return on capital | — | — | 0.5% | 16.3% | 7.2% | −14.5% | −13.5% | −4.1% | 2.2% | 7.5% |
| Return on equity | 0.1% | 9.4% | 0.1% | 16.1% | 6.7% | −13.2% | −12.7% | −4.5% | 1.7% | 6.8% |
| Return on assets | 0.3% | 10.9% | 0.1% | 11.3% | 5.1% | −9.5% | −7.8% | −2.5% | 0.9% | 3.3% |
| Net debt to EBITDA | — | — | −1.1x | −0.3x | −1.4x | — | — | — | −0.5x | 0.5x |